Zobrazeno 1 - 10
of 35
pro vyhledávání: '"329"'
Autor:
Alok A. Khorana, Fahrettin Covut, Yihong Zhou, Shafia Rahman, Shab E Gul Rahim, Sudha Amarnath
Publikováno v:
Blood. 132:1242-1242
Background:Venous thromboembolism (VTE) is a highly prevalent complication of cancer and its treatment and is commonly treated with anticoagulation1. However, there are limited data regarding the use of therapeutic anticoagulation in patients with br
Autor:
Auro Viswabandya, Hans A. Messner, Dennis Dong Hwan Kim, Jieun Uhm, Marc Poch Martell, Elizabeth Shin, Jeffrey H. Lipton, Fotios V. Michelis
Publikováno v:
Blood. 126:3139-3139
Introduction: Chronic graft versus host disease (cGVHD) is one of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Several prognostic factors have been proposed to predict the outcomes of cGVHD including progres
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of
Autor:
Maanasa Gowda, Franco Locatelli, Tommaso Stefanelli, Norbert Hollaender, Shahrukh K. Hashmi, Robert Zeiser, Mary E.D. Flowers, Fitzroy Dawkins, Ronjon Chakraverty, Stephanie J. Lee, Nicola Polverelli, Takanori Teshima, Ron Ram
Publikováno v:
Blood. 136:22-24
BACKGROUND Standard first-line treatment of cGVHD includes systemic corticosteroids; however, about 50% of patients (pts) are steroid refractory or dependent (SR/D) and require additional treatment. The best second-line therapy option has not yet bee
Autor:
U. Creutzig, P. Smisek, L. Hovi, B. Stark, B. Gibson, B. Razzouk, Carmelo Rizzari, R. Tamminga, G.J.L. Kaspers, A. Baruchel, S. Ha, D. Reinhardt, Y. Bertrand, M. Zimmermann, H. Armendariz, Alexei Maschan, M. Dworzak, O. Smith
Publikováno v:
Blood. 112:2977-2977
Relapse remains the commonest adverse event in newly diagnosed AML patients, and the reported long-term survival after relapse in pediatric AML is 20–30%. Allogeneic stem cell transplantation (allo-SCT) in CR1 is employed by several groups with the
Autor:
Franco Locatelli, Tommaso Stefanelli, Valkal Bhatt, Shashikant Apte, Nada Hamad, Stephanie J. Lee, Francesca Bonifazi, Takanori Teshima, Jackie Han, Kentaro Fukushima, Maanasa Gowda, Ivan S. Moiseev, Juan Carlos Vallejo Llamas, Joseph Pidala, Francis Ayuk, Robert Zeiser, Tsila Zuckerman, Mike Zuurman
Publikováno v:
Blood. 138:3909-3909
BACKGROUND Approximately 50% of patients (pts) who receive initial cGVHD therapy are steroid refractory or dependent (SR/D); standard second-line therapy has yet to be established. Quality of life (QOL) in these pts is poor and worsens with disease s
Autor:
Jian-Ping Zhang, Rui-Juan Sun, Peihua Lu, Junfang Yang, Xian Zhang, Yan-Li Zhao, Jingjing Li, Min Xiong, Jia-Rui Zhou, De-Yan Liu, Yue Lu, Xing-Yu Cao, Zhi-Jie Wei
Publikováno v:
Blood. 136:40-41
Introduction Current available treatments are limited once patients with B-ALL relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT). While chimeric antigen receptor (CAR) T-cell therapy offers a chance of remission, long-t
Autor:
Shanta Chawla, Manuel Modiano, Jayaram S. Bharadwaj, Jawad Francis, Hlalah Osama, Lee S. Schwartzberg, Nishan Tchekmedyian, Francois Lebel, Gajanan Bhat
Publikováno v:
Blood. 136:34-35
Background: Eflapegrastim (Rolontis®, Efla) is a long-acting granulocyte-colony stimulating factor (G-CSF), consisting of a recombinant human G-CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Efla is not a b
Autor:
Evandro D. Bezerra, Brenda M. Sandmaier, Linde M. Morsink, Megan Othus, H. Joachim Deeg, H. Gary Schoch, Brent L. Wood, Min Fang, Frederick R. Appelbaum, Roland B. Walter
Publikováno v:
Blood. 134:321-321
Background:Myeloablative allogeneic hematopoietic cell transplantation (HCT) is a common post-remission treatment strategy for medically fit adults with acute myeloid leukemia (AML) in morphologic remission. Several conditioning regimens have been ut
Autor:
Tony Reiman, Donna E. Reece, Eshetu G. Atenafu, Martha L Louzada, Christopher P. Venner, Muhammad Aslam, Michael Sebag, Kevin W. Song, Arleigh McCurdy, Richard Leblanc, Esther Masih-Khan, Julie Stakiw, Darrell White, Engin Gul, Rami Kotb, Victor H Jimenez-Zepeda
Publikováno v:
Blood. 134:1886-1886
Lenalidomide in combination with dex (Len + dex) was introduced as treatment for relapsed/refractory myeloma in Canada over a decade ago; more recently, Len has been routinely available as part of first-line therapy, both in transplant-eligible patie